Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program

Kai Hübel(University Hospital Cologne), Nicolaus Kröger(Universität Hamburg), Martin Ebinger(University Children's Hospital Tübingen), Wolf Rösler, Frank Heits(Agaplesion Diakonieklinikum Rotenburg), R Hartwig(BG Klinikum Duisburg), Norbert Frickhofen(Helios Dr. Horst Schmidt Kliniken Wiesbaden), Sabine Dressler(Nuremberg Hospital), Michael H. Albert(LMU Klinikum), Maximilian Christopeit(Universität Hamburg), Maximilian M. Fresen(University Hospital Cologne), Dominik Wehler(Johannes Gutenberg University Mainz), Sebastian Theurich(University Hospital Cologne), Christian Weigelt(Heinrich Heine University Düsseldorf), Nadežda Basara(Malteser-Krankenhaus), Michael Kiehl(Klinikum Frankfurt Höchst), Florian Lordick(Leipzig University), Bernd Hertenstein(San Antonio College), Oliver Galm(Universitätsklinikum Aachen), Hans Salwender(Asklepios Klinik Altona), Florian Lange(University Hospital Cologne), Simone Liebler(Universitätsklinikum Gießen und Marburg), M von Lilienfeld-Toal(University of Bonn), Eckhart Weidmann(Krankenhaus Nordwest), A R Zander(Universität Hamburg), Christian Bogner(TUM Klinikum), Rita Beier(Medizinische Hochschule Hannover)
Bone Marrow Transplantation
October 25, 2010
10.1038/bmt.2010.249
Cited by 79

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k